sorafenib has been researched along with uridine diphosphate in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (uridine diphosphate) | Trials (uridine diphosphate) | Recent Studies (post-2010) (uridine diphosphate) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,164 | 4 | 536 |
| Protein | Taxonomy | sorafenib (IC50) | uridine diphosphate (IC50) |
|---|---|---|---|
| UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Gharbieh, E; Abushawish, KYI; Al-Hroub, HM; Alzoubi, KH; Bustanji, Y; El-Huneidi, W; Elgendy, SM; Giddey, AD; Mousa, M; Omar, HA; Semreen, MH; Soares, NC; Soliman, SSM | 1 |
| Cui, Y; Dong, Z; Fu, Y; He, X; Li, Y; Ma, Y; Xun, X | 1 |
2 other study(ies) available for sorafenib and uridine diphosphate
| Article | Year |
|---|---|
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
Topics: Alanine; Amino Acids; Antineoplastic Agents; Biomarkers; Calpain; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Folic Acid Antagonists; Glucose; Humans; L-Iditol 2-Dehydrogenase; Liver Neoplasms; Metabolic Networks and Pathways; Nucleotides; Phosphatidylcholines; Proline; Protein Kinase Inhibitors; Proteome; Proteomics; Sorafenib; Succinic Acid; Superoxide Dismutase; Tyrosine; Ubiquitin Thiolesterase; Uridine Diphosphate | 2022 |
Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
Topics: Acetonitriles; Animals; Benzhydryl Compounds; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glucuronosyltransferase; Liver Neoplasms; Rats; Reproducibility of Results; RNA, Messenger; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib; Tandem Mass Spectrometry; Uridine Diphosphate | 2022 |